You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港大有份研發噴鼻式新冠疫苗獲內地批准緊急使用
阿思達克 12-06 11:13
港大微生物學系與廈門大學及萬泰生物合作開發的噴鼻式新冠疫苗,已獲得內地批准緊急使用。 萬泰生物宣布,噴鼻式疫苗已獲得國家藥品監督管理局開啟關鍵綠燈,目標是於未來半年內生產2億劑,該疫苗每人只需接種一劑。港大團隊表示,何時可於香港使用,需待特區政府批准。 疫苗已於內地、香港及東南亞等地,分別經過三期臨床試驗;第三期試驗顯示疫苗於曾接種滅活疫苗的人群之中,對Omicron變種病毒有超過80%保護效力,對未曾接種疫苗的人士保護力則為55%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account